- Yunnan Baiyao reported a net income of 1.70 billion yuan for the second quarter of 2025.
- The revenue for the first half of 2025 amounted to 21.26 billion yuan, representing a 3.9% year-over-year increase.
- The company has a favorable analyst sentiment with 20 buy ratings, no hold or sell ratings reported.
A look at Yunnan Baiyao Group Co., Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
In assessing the long-term outlook for Yunnan Baiyao Group Co., various factors play a crucial role. The company’s favorable Smart Scores across key areas such as Value, Dividend, Growth, and Resilience indicate a strong foundation for future performance. With a noteworthy score in each of these categories, Yunnan Baiyao Group Co. appears well-positioned to weather market fluctuations and benefit from growth opportunities. However, it is worth noting that the Momentum score, though lower in comparison, suggests some room for improvement in seizing market trends swiftly.
Yunnan Baiyao Group Co., Ltd., known for manufacturing traditional Chinese medicines and engaging in various business segments including pharmaceutical trading, empty capsules manufacturing, and hotel operations, exhibits a robust overall outlook. The company’s solid Smart Scores underline its attractive valuation, dividend potential, growth prospects, and resilience in the face of challenges. These factors combined position Yunnan Baiyao Group Co. for long-term success and sustainability in its diverse business operations.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars
